Berg, Hege F.
Ju, Zhenlin
Myrvold, Madeleine
Fasmer, Kristine E.
Halle, Mari K.
Hoivik, Erling A.
Westin, Shannon N.
Trovik, Jone
Haldorsen, Ingfrid S.
Mills, Gordon B.
Krakstad, Camilla
Werner, Henrica M. J.
Funding for this research was provided by:
Universitetet i Bergen
Kreftforeningen
Article History
Received: 9 October 2019
Revised: 8 January 2020
Accepted: 15 January 2020
First Online: 10 February 2020
Ethics approval and consent to participate
: All parts of the study have been approved according to Norwegian legislation and Western Regional Committee for Medical and Health Research Ethics (REK 2009/2315 and 2014/1907) and according to the Institutional Review Board of MDACC (Lab08-0580). All included patients signed written informed consent. The study was performed in accordance with the Declaration of Helsinki.
: N/A
: N/A
: The authors declare no competing interests.
: The study was supported by the University of Bergen and the Norwegian Cancer Society. Investigators were supported by NIH K12 Calabresi Scholar Award (K12ExternalRef removed) to S.N.W., NCI SPORE in Uterine Cancer (2P50ExternalRef removed-06) to S.N.W., GBM and NCI Cancer Centre Support Grant (P30ExternalRef removed) to MD Anderson Cancer Centre. None of the funding sources were involved in collecting, analysing or interpreting data, nor writing the article or deciding to submit for publication.